HeartMate 3 LVAD

With Full Maglev Flow Technology

About HeartMate 3 LVAD

The HeartMate​ 3™​ Left Ventricular Assist Device (LVAD) is a mechanical circulatory support device designed for patients with advanced heart failure. With significantly improved outcomes and survival comparable to heart transplant at 2 years, our LVAD technology is making a better future possible for many patients with advanced heart failure.*1-3 The HeartMate​ 3 LVAD has advanced the field of LVAD therapy and is setting the standard with innovation and outstanding clinical outcomes.1

The Full MagLev Flow Technology within the HeartMate 3 LVAD maintains gentle blood handling to minimize complications and hemocompatibility-related adverse events.

HeartMate 3 LVAD with Full MagLev Flow Technology offers

  • Fully levitated, self-centering rotor, which does not require hydrodynamic or mechanical bearings
  • Large, consistent blood flow pathways, which reduces shear stress4
  • Intrinsic pulsatility, which reduces stasis and minimize thrombus4,5
Cut across view of the HeartMate 3 Maglev Pump
Product details

HeartMate 3 LVAD Product Information

HeartMate 3 LVAD Clinical Evidence

There are comprehensive clinical evidence materials available to learn about the survival rate and patient improvement associated with the HeartMate 3 LVAD. For a deep dive into the clinical data, visit the Clinical Evidence and Journal Article information.

Highlights from Long-Term MOMENTUM 3 Study

In the largest LVAD trial ever conducted, clinicians studied the safety and effectiveness of the HeartMate 3 LVAD in patients with advanced heart failure and who were indicated for mechanical circulatory support with an LVAD. The study showed:

79% 2-year survival rate
80% of patients saw Sustained Improvement

Improved Safety Profile

10% Stroke | 1% Thrombosis

Lowest hemocompatibility-related adverse events of any LVAD§*1,8-10

HeartMate 3 LVAD Education and Training

For the safe and effective management of advanced heart failure with the HeartMate 3 LVAD, we provide comprehensive educational resources. The following resources are designed to help you better understand patient education, use cases, surgical procedure and more.

Manuals & Resources

Manuals & Resources

Customer Service

Customer Service

This device is commercially available for use in select international markets.

*Based on published data from separate datasets, which may involve different patient populations and other variables. Not a head-to-head comparison. Data presented for informational purposes only.

§For a continuous-flow LVAD in a randomized controlled trial.


  1. Mehra M, Uriel N, Naka Y, et al. A Fully Magnetically Levitated Left Ventricular Assist Device-Final Report. N Engl J Med. 2019;380:1618-1627.
  2. Khush KK, Cherikh WS, Chambers DC, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-fifth Adult Heart Transplant Report-2018; Focus Theme: Multiorgan Transplantation. J Heart Lung Transplant. 2018;37:1155-1168.
  3. Teuteberg JJ, Cleveland JC Jr, Cowger J, et al. The Society of Thoracic Surgeons Intermacs 2019 Annual Report: The Changing Landscape of Devices and Indications. Ann Thorac Surg. March 2020;109(3):649-660.
  4. Bourque K, Cotter C, Dague C, et al. Design rationale and preclinical evaluation of the HeartMate 3 Left Ventricular Assist System for hemocompatibility. Am Soc Artificial Int Organs. 2016;62:375-383.
  5. Bourque K, Dague C, Farrar D, et al. In vivo assessment of a rotary left ventricular assist device-induced artificial pulse in the proximal and distal aorta. Artificial Organs. 2006;30:638-642.
  6. Abbott data on file.
  7. Mehra MR. A Fully Magnetically Levitated Left Ventricular Assist Device-Final Report for the MOMENTUM 3 Trial. American College of Cardiology (ACC) Annual Meeting; March 17, 2019; New Orleans, LA.
  8. Rogers JG, Pagani F, Tatooles A, et al. Intrapericardial left ventricular assist device for advanced heart failure. New Engl J Med. 2017;376:451-460.
  9. Markham DW. Two-year Outcomes in the ENDURANCE Supplemental Trial. American Heart Association (AHA) Annual Meeting; November 10, 2018; Chicago, IL.
  10. Uriel N. Long-Term Burden of Hemocompatibility Related Adverse Events in the MOMENTUM 3 Trial: Final Analysis of the 1028 Patient Cohort. The International Society for Heart & Lung Transplantation (ISHLT) Annual Meeting; April 4, 2019; Orlando, FL.

MAT-2106243 v1.0